Table 1.
Number of patients with driver or resistance mutations detected in tumor and plasma, as well as sensitivity and specificity. Sensitivity estimates are based on Group 1, in which tumor variants were detected in the plasma. Specificity estimates are based on Group 2, in which tumor samples tested negative for driver mutations by NGS
| Group 1 (n = 91) Driver positive on tissue genotyping |
Group 2 (n = 19) Driver negative on tissue NGS | Group 3 (n=17) Driver unknown insufficient tissue | |||
|---|---|---|---|---|---|
| Detected in tumor | Tumor variant detected in plasma, N (sensitivity) | Detected in plasma, N (specificity) | Detected in plasma | ||
| Driver | Total Subjects | 91 | 68 (75%) | 0 (100%) | 4 |
| EGFR | 37 | 29 (78%) | 0 | 0 | |
| KRAS | 29 | 23 (79%) | 0 | 4 | |
| ALK | 8 | 5 (62%) | 0 | 0 | |
| MET | 6 | 3 (50%) | 0 | 0 | |
| ERBB2 | 4 | 4 (100%) | 0 | 0 | |
| BRAF | 3 | 3 (100%) | 0 | 0 | |
| ROS1 | 3 | 1 (33%) | 0 | 0 | |
| RET | 1 | 0 (0%) | 0 | 0 | |
| Resistance | EGFR | 13 | 11 (85%) | NA | NA |
| MET | 2 | 0 (0%) | NA | NA | |
NGS, next-generation sequencing.